Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2012 on request of the Sponsor.

On 5 September 2008, orphan designation (EU/3/08/560) was granted by the European Commission to KeyNeurotek Pharmaceuticals AG, Germany, for (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brain injury.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Disease / condition
Treatment of moderate and severe closed traumatic brain injury
Date of decision
Orphan decision number

Sponsor's contact details

KeyNeurotek Pharmaceuticals AG
Zenit-Technology Park
Leipzigerstr. 44
39120 Magdeburg
Tel. + 49 391 6117 220
Gax: + 49 391 6117 221

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating